Momont, Corey
Dang, Ha V.
Zatta, Fabrizia
Hauser, Kevin
Wang, Caihong
di Iulio, Julia http://orcid.org/0000-0001-9343-127X
Minola, Andrea
Czudnochowski, Nadine
De Marco, Anna
Branch, Kaitlin
Donermeyer, David
Vyas, Siddhant
Chen, Alex http://orcid.org/0000-0003-2620-5066
Ferri, Elena
Guarino, Barbara
Powell, Abigail E.
Spreafico, Roberto http://orcid.org/0000-0001-8282-7658
Yim, Samantha S. http://orcid.org/0009-0007-8567-3501
Balce, Dale R.
Bartha, Istvan
Meury, Marcel
Croll, Tristan I.
Belnap, David M. http://orcid.org/0000-0002-0619-7487
Schmid, Michael A. http://orcid.org/0000-0002-1137-9322
Schaiff, William Timothy
Miller, Jessica L.
Cameroni, Elisabetta
Telenti, Amalio http://orcid.org/0000-0001-6290-7677
Virgin, Herbert W.
Rosen, Laura E. http://orcid.org/0000-0002-8030-0219
Purcell, Lisa A. http://orcid.org/0000-0002-9565-2030
Lanzavecchia, Antonio
Snell, Gyorgy http://orcid.org/0000-0003-1475-659X
Corti, Davide http://orcid.org/0000-0002-5797-1364
Pizzuto, Matteo Samuele http://orcid.org/0000-0001-5776-654X
Article History
Received: 19 September 2022
Accepted: 26 April 2023
First Online: 31 May 2023
Change Date: 5 July 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-023-06385-x
Competing interests
: C.M., H.V.D., F.Z., K.H., C.W., J.d.I., A.M., N.C., A.D.M., K.B., D.D., S.V., A.C., B.G., A.E.P., S.S.Y., D.R.B., I.B., M.M., M.A.S., W.T.S., J.L.M., E.C., A.T., L.E.R., L.A.P., A.L., G.S., D.C. and M.S.P. are employees of and may hold shares in Vir Biotechnology. D.C., M.S.P., A.M., E.C., G.S., K.H., C.M. and E.F. are currently listed as inventors on multiple patent applications, which disclose the subject matter described in this paper. E.F., A.E.P., R.S. and H.W.V. are former employees of VIR Biotechnology. E.F. is currently an employee at and hold stocks in Amgen. Amgen provided no funding for this work. T.I.C. is a consultant for Vir Biotechnology and receives royalties from licensing of ISOLDE software used for molecular modelling. D.M.B. received research funding from VIR Biotechnology. L.A.P. is a former employee and shareholder of Regeneron Pharmaceuticals and is a member of the Scientific Advisory Board AI-driven structure-enabled antiviral platform (ASAP). Regeneron provided no funding for this work. H.W.V. is a founder of PierianDx and Casma Therapeutics. Neither company provided funding for this work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interest.